AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1472662 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 micrograms/kg), IV, after termination of CPB and saline (placebo) 12 hours later in the ICU
Number of subjects: 70
Study 1472662 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) IV after CPB and 12 hours later in the ICU
Number of subjects: 70
Study 6585285 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (0.5 mg)
Number of subjects: 18
Study 6585285 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (1.0 mg)
Number of subjects: 18
Study 6585285 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (2.0 mg)
Number of subjects: 18
Study 6585285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31184016 — intervention group
Group type: EXPERIMENTAL
Intervention: Serenoa repens in combination with Urtica dioiccus 160/120 mg twice daily for 3 months
Number of subjects: 102
Study 31184016 — intervention group
Group type: COMPARATOR
Intervention: Serenoa repens 320 mg once a day for 3 months
Number of subjects: 102
Study 28598553 — intervention group
Group type: EXPERIMENTAL
Intervention: Base intervention (20-week storybook-based intervention)
Number of subjects: 6483
Study 28598553 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced version with extended professional development for educators
Number of subjects: 6483
Study 28598553 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based program for parents
Number of subjects: 6483
Study 28598553 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 6483
Study 27174723 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher effort at easier task difficulty (shorter PEP)
Number of subjects: 0
Study 27174723 — intervention group
Group type: EXPERIMENTAL
Intervention: Diminished effort at harder task difficulty (longer PEP)
Number of subjects: 0
Study 24394584 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐ brush+F‐ rinse 2× per day
Number of subjects: 12
Study 24394584 — intervention group
Group type: COMPARATOR
Intervention: F‐ brush+F‐ rinse once a day
Number of subjects: 12
Study 24394584 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐ brush+rinsing with 0.05% NaF after lunch
Number of subjects: 12
Study 24394584 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐ brush+F‐ rinse before bedtime
Number of subjects: 12
Study 24394584 — intervention group
Group type: COMPARATOR
Intervention: F‐ brush
Number of subjects: 12
Study 23318614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesser tuberosity osteotomy
Number of subjects: 86
Study 23318614 — intervention group
Group type: COMPARATOR
Intervention: Subscapularis peel
Number of subjects: 86
Study 21111309 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow-tinted IOLs (AF-1 (UY), AcrySof SN60AT)
Number of subjects: 80
Study 21111309 — intervention group
Group type: COMPARATOR
Intervention: Clear IOLs (AF-1 (UV), AcrySof SA60AT)
Number of subjects: 80
Study 18490214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 80
Study 18490214 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 80
Study 15690408 — intervention group
Group type: EXPERIMENTAL
Intervention: CD‐ROM only
Number of subjects: 197
Study 15690408 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback to counselor only
Number of subjects: 197
Study 15690408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CD‐ROM and feedback
Number of subjects: 197
Study 15690408 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 197
Study 12610802 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Tripterygium wilfordii (TW)
Number of subjects: 61
Study 12610802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 10730525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin (0.2 mg/kg initially, then 0.1 mg/kg every 12 hours for 2 more doses)
Number of subjects: 30
Study 10730525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10730525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin
Number of subjects: 30
Study 7723643 — intervention group
Group type: EXPERIMENTAL
Intervention: Large fluid replacement (Large FR) - 1330 +/- 60 ml of a 6% carbohydrate solution (79 +/- 4 g)
Number of subjects: 8
Study 7723643 — intervention group
Group type: COMPARATOR
Intervention: Small fluid replacement (Small FR) - 200 +/- 10 ml of a 40% maltodextrin solution (79 +/- 4 g)
Number of subjects: 8
Study 7723643 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO) - 6% carbohydrate solution (79 +/- 4 g)
Number of subjects: 8
Study 7723643 — intervention group
Group type: COMPARATOR
Intervention: No carbohydrate ingestion (NO CHO) - water
Number of subjects: 8
Study 2119958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tetrandrine (0.12 to 0.21 g)
Number of subjects: 27
Study 2119958 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 27
Study 2119958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tetrandrine
Number of subjects: 27
Study 121640 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 15 microgram and ethinyloestradiol 30 microgram
Number of subjects: 0
Study 121640 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 50 microgram with ethinyloestradiol 50 microgram for 11 days, followed by levonorgestrel 125 microgram for 11 days, followed by levonorgestrel 125 microgram with ethinyloestradiol 50 microgram for 10 days
Number of subjects: 0
Study 121640 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31168688 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg BD
Number of subjects: 10
Study 31168688 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 10
Study 28865915 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed Loop Anaesthesia Delivery System (CLADS)
Number of subjects: 40
Study 28865915 — intervention group
Group type: COMPARATOR
Intervention: Target Controlled Infusion (TCI)
Number of subjects: 40
Study 26630923 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB) scores
Number of subjects: 48
Study 23059865 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training group (STG)
Number of subjects: 33
Study 23059865 — intervention group
Group type: COMPARATOR
Intervention: Doctor advice group (DAG)
Number of subjects: 33
Study 21596588 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics administered 5 minutes before exsanguination and inflation of the tourniquet (ABT)
Number of subjects: 106
Study 21596588 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic antibiotics administered 1 minute after inflation of the tourniquet (AAT)
Number of subjects: 106
Study 18302700 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 315
Study 18302700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 17196059 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 100
Study 17196059 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine
Number of subjects: 100
Study 17196059 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 100
Study 17196059 — intervention group
Group type: COMPARATOR
Intervention: Serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine
Number of subjects: 100
Study 12728082 — intervention group
Group type: EXPERIMENTAL
Intervention: PMF formula (Enfamil with iron) containing PO/coconut/soy/high-oleic sunflower oils (45/20/20/15% oil)
Number of subjects: 128
Study 12728082 — intervention group
Group type: COMPARATOR
Intervention: Milk-based formula without PO (Similac with iron) containing high-oleic safflower/coconut/soy oils (40/30/30% oil)
Number of subjects: 128
Study 10918548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM), n = 651
Number of subjects: 1298
Study 10918548 — intervention group
Group type: COMPARATOR
Intervention: Casual blood pressure measurement in the physician's practice (PM), n = 647
Number of subjects: 1298
Study 10918548 — intervention group
Group type: EXPERIMENTAL
Intervention: ABPM, n = 651
Number of subjects: 1298
Study 10918548 — intervention group
Group type: COMPARATOR
Intervention: PM, n = 647
Number of subjects: 1298
Study 1426223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 10
Study 1426223 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 10
Study 4050842 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg sublingual nifedipine
Number of subjects: 30
Study 4050842 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sublingual nifedipine
Number of subjects: 30
Study 4050842 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual nifedipine
Number of subjects: 30
Study 31246604 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetized arm
Number of subjects: 12
Study 31246604 — intervention group
Group type: COMPARATOR
Intervention: Awake arm
Number of subjects: 12
Study 31246604 — intervention group
Group type: EXPERIMENTAL
Intervention: Female subjects
Number of subjects: 12
Study 31246604 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-kg increase in body weight
Number of subjects: 12
Study 29322167 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk plaque detected by coronary CTA
Number of subjects: 4415
Study 26761270 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination cognitive behavioral therapy and medication management algorithm (COMB)
Number of subjects: 44
Study 26761270 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 44
Study 24834933 — intervention group
Group type: EXPERIMENTAL
Intervention: oVEMP test after 12 hours sleep deprivation
Number of subjects: 20
Study 24834933 — intervention group
Group type: COMPARATOR
Intervention: oVEMP test after normal sleep
Number of subjects: 20
Study 24834933 — intervention group
Group type: EXPERIMENTAL
Intervention: cVEMP test after 12 hours sleep deprivation
Number of subjects: 20
Study 24834933 — intervention group
Group type: COMPARATOR
Intervention: cVEMP test after normal sleep
Number of subjects: 20
Study 22538693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted technique
Number of subjects: 6
Study 22538693 — intervention group
Group type: COMPARATOR
Intervention: Non-cap technique
Number of subjects: 6
Study 20657612 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of the renin-angiotensin system
Number of subjects: 0
Study 20657612 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18622895 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin olive oil
Number of subjects: 38
Study 18622895 — intervention group
Group type: EXPERIMENTAL
Intervention: Common olive oil
Number of subjects: 38
Study 18622895 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined olive oil
Number of subjects: 38
Study 18622895 — intervention group
Group type: EXPERIMENTAL
Intervention: Low phenolic olive oil
Number of subjects: 38
Study 18622895 — intervention group
Group type: COMPARATOR
Intervention: Medium phenolic olive oil
Number of subjects: 38
Study 18622895 — intervention group
Group type: COMPARATOR
Intervention: High phenolic olive oil
Number of subjects: 38
Study 15714903 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic head movements
Number of subjects: 1
Study 12120777 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond
Number of subjects: 0
Study 12120777 — intervention group
Group type: EXPERIMENTAL
Intervention: PermaQuik
Number of subjects: 0
Study 12120777 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Up Bond F
Number of subjects: 0
Study 10413893 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate (MFP) 15 mg F/day for 18 months
Number of subjects: 0
Study 10413893 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride (NaF) 30 mg F/day for 18 months
Number of subjects: 0
Study 10413893 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride (NaF) 30 mg F/day
Number of subjects: 0
Study 10413893 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate (MFP) 15 mg F/day
Number of subjects: 0
Study 8543385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) and Vindesine (Eldesine) with addition of Cisplatin (Platinol)
Number of subjects: 87
Study 8543385 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) and Vindesine (Eldesine) without Cisplatin (Platinol)
Number of subjects: 87
Study 1900225 — intervention group
Group type: EXPERIMENTAL
Intervention: urokinase-preactivated prourokinase
Number of subjects: 55
Study 1900225 — intervention group
Group type: COMPARATOR
Intervention: tissue-type plasminogen activator
Number of subjects: 55
Study 1900225 — intervention group
Group type: EXPERIMENTAL
Intervention: thrombin-antithrombin III complex levels greater than 6 ng/l
Number of subjects: 55
Study 6132852 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg intramuscularly
Number of subjects: 24
Study 6132852 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg orally
Number of subjects: 24
Study 6132852 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol, 0.07 mg/kg subcutaneously
Number of subjects: 24
Study 6132852 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (26 normal gastric emptying rate)
Number of subjects: 24
Study 31004213 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training (HIT) for 8 weeks, followed by 8 weeks of self-training
Number of subjects: 10
Study 31004213 — intervention group
Group type: COMPARATOR
Intervention: No training for 8 weeks followed by non-supervised HIT for 8 weeks
Number of subjects: 10
Study 28257378 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/day fluocinolone acetonide (FAc)
Number of subjects: 100
Study 28257378 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 100
Study 27281531 — intervention group
Group type: EXPERIMENTAL
Intervention: TEV‐48125 675/225 mg
Number of subjects: 261
Study 27281531 — intervention group
Group type: EXPERIMENTAL
Intervention: TEV‐48125 900 mg
Number of subjects: 261
Study 27281531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 24614572 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM)
Number of subjects: 310
Study 24614572 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory follow-ups (control)
Number of subjects: 310
Study 22840457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (GBT + conventional treatment)
Number of subjects: 80
Study 22840457 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (control group)
Number of subjects: 80
Study 19815939 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-field digital retinal imaging (WFDRI)
Number of subjects: 76
Study 19815939 — intervention group
Group type: COMPARATOR
Intervention: Binocular indirect ophthalmoscopy (BIO)
Number of subjects: 76
Study 17691587 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe‐59 labeled iron(III)‐hydroxide polymaltose complex (IPC, Maltofer) equivalent to 100 mg elemental iron
Number of subjects: 22
Study 17691587 — intervention group
Group type: COMPARATOR
Intervention: Fe‐59 labeled IPC complex equivalent to 100 mg elemental iron and 500 mg tetracycline HCl
Number of subjects: 22
Study 16013427 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12011578 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk providing 25 g/day of protein
Number of subjects: 20
Study 12011578 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk (identically formulated)
Number of subjects: 20
Study 10445772 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg and placebo infusion
Number of subjects: 79
Study 10445772 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (remifentanil 1 microg/kg and infusion of 0.2 microg/kg/min)
Number of subjects: 79
Study 10445772 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil 7 microg/kg and placebo infusion
Number of subjects: 79
Study 7796715 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg i.v. cocaine
Number of subjects: 0
Study 1756260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (HDMA) at doses of 480, 800, 1280, and 1600 mg/d
Number of subjects: 57
Study 1756260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (HDMA)
Number of subjects: 57
Study 7181824 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise presented during reported hallucinations
Number of subjects: 3
Study 7181824 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise followed hallucinations
Number of subjects: 3
Study 7181824 — intervention group
Group type: COMPARATOR
Intervention: Control condition (white noise presented randomly)
Number of subjects: 3
Study 31475635 — intervention group
Group type: EXPERIMENTAL
Intervention: Active case finding (ACF)
Number of subjects: 572
Study 31475635 — intervention group
Group type: COMPARATOR
Intervention: Passive case finding (PCF)
Number of subjects: 572
Study 28403458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation intervention
Number of subjects: 207
Study 25406967 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/d eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ready‐to‐eat meals enriched with liquid fish oil
Number of subjects: 99
Study 25406967 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/d eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as microencapsulated fish oil powder and regular meals
Number of subjects: 99
Study 25406967 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder and regular meals
Number of subjects: 99
Study 25253543 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic Apathia Scale
Number of subjects: 56
Study 22728292 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2 g/d
Number of subjects: 133
Study 22728292 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3 g/d
Number of subjects: 133
Study 22728292 — intervention group
Group type: COMPARATOR
Intervention: AZA
Number of subjects: 133
Study 19958860 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEpo) 200 U/kg daily for 3 consecutive days
Number of subjects: 44
Study 19958860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 17325502 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20
Study 17325502 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20
Study 15077243 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic diary
Number of subjects: 20
Study 15077243 — intervention group
Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 20
Study 12201939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical IFN gamma (0.7 mg per week for 8 weeks)
Number of subjects: 54
Study 12201939 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated after transurethral resection)
Number of subjects: 54
Study 12201939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical IFN gamma
Number of subjects: 54
Study 9659016 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sevoflurane
Number of subjects: 36
Study 9659016 — intervention group
Group type: COMPARATOR
Intervention: 2.5% halothane
Number of subjects: 36
Study 8567768 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (Norditropin, 12 IU/day, i.m., for 7 days)
Number of subjects: 30
Study 8567768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2653217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus netilmicin
Number of subjects: 214
Study 2653217 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin plus netilmicin
Number of subjects: 214
Study 305467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar stimulation for two periods of 24 hours
Number of subjects: 11
Study 305467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar stimulation
Number of subjects: 11
Study 29166767 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX)
Number of subjects: 120
Study 29166767 — intervention group
Group type: EXPERIMENTAL
Intervention: boiled water
Number of subjects: 120
Study 29166767 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 120
Study 28257242 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer network interventions (n=47)
Number of subjects: 47
Study 28257242 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual control group (n=48)
Number of subjects: 47
Study 25301816 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies including flexible scheduling, convenient locations, and incentives
Number of subjects: 430
Study 25301816 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant demographics and health characteristics
Number of subjects: 430
Study 25301816 — intervention group
Group type: EXPERIMENTAL
Intervention: History of excessive drinking and drug use
Number of subjects: 430
Study 24060302 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training group (N=35)
Number of subjects: 65
Study 24060302 — intervention group
Group type: COMPARATOR
Intervention: Cadaver eyes training group (N=30)
Number of subjects: 65
Study 23171246 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow eating rate
Number of subjects: 30
Study 23171246 — intervention group
Group type: COMPARATOR
Intervention: Fast eating rate
Number of subjects: 30
Study 19656359 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of stroke risk factors and warning signs
Number of subjects: 2033
Study 19656359 — intervention group
Group type: COMPARATOR
Intervention: Education level
Number of subjects: 2033
Study 19656359 — intervention group
Group type: COMPARATOR
Intervention: Geographic location
Number of subjects: 2033
Study 17717235 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mL water
Number of subjects: 10
Study 17717235 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mL water
Number of subjects: 10